Suven Pharmaceuticals Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Suven Pharmaceuticals şirketinin toplam hissedar öz sermayesi ₹20.3B ve toplam borcu ₹90.7M olup, bu da borç-öz sermaye oranını 0.4% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla ₹25.1B ve ₹4.8B dir. Suven Pharmaceuticals 'in FAVÖK'ü ₹2.7B faiz karşılama oranı 46.6 dur. Şirketin ₹6.6B tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

0.4%

Borç/özkaynak oranı

₹90.70m

Borç

Faiz karşılama oranı	46.6x
Nakit	₹6.56b
Eşitlik	₹20.28b
Toplam yükümlülükler	₹4.77b
Toplam varlıklar	₹25.06b

Son finansal sağlık güncellemeleri

These 4 Measures Indicate That Suven Pharmaceuticals (NSE:SUVENPHAR) Is Using Debt Safely

Dec 15

Does Suven Pharmaceuticals (NSE:SUVENPHAR) Have A Healthy Balance Sheet?

May 12

These 4 Measures Indicate That Suven Pharmaceuticals (NSE:SUVENPHAR) Is Using Debt Safely

Nov 30

Here's Why Suven Pharmaceuticals (NSE:SUVENPHAR) Can Manage Its Debt Responsibly

Aug 04

Does Suven Pharmaceuticals (NSE:SUVENPHAR) Have A Healthy Balance Sheet?

Mar 08

Recent updates

These 4 Measures Indicate That Suven Pharmaceuticals (NSE:SUVENPHAR) Is Using Debt Safely

Dec 15

Robust Earnings May Not Tell The Whole Story For Suven Pharmaceuticals (NSE:SUVENPHAR)

Aug 03

Does Suven Pharmaceuticals (NSE:SUVENPHAR) Have A Healthy Balance Sheet?

May 12

Suven Pharmaceuticals Limited (NSE:SUVENPHAR) Investors Are Less Pessimistic Than Expected

Mar 26

Here's Why We Think Suven Pharmaceuticals (NSE:SUVENPHAR) Is Well Worth Watching

Mar 07

These 4 Measures Indicate That Suven Pharmaceuticals (NSE:SUVENPHAR) Is Using Debt Safely

Nov 30

Do Suven Pharmaceuticals's (NSE:SUVENPHAR) Earnings Warrant Your Attention?

Sep 03

Here's Why Suven Pharmaceuticals (NSE:SUVENPHAR) Can Manage Its Debt Responsibly

Aug 04

Analysts Have Made A Financial Statement On Suven Pharmaceuticals Limited's (NSE:SUVENPHAR) Full-Year Report

Jun 11

With EPS Growth And More, Suven Pharmaceuticals (NSE:SUVENPHAR) Is Interesting

Apr 13

Does Suven Pharmaceuticals (NSE:SUVENPHAR) Have A Healthy Balance Sheet?

Mar 08

Can Suven Pharmaceuticals Limited's (NSE:SUVENPHAR) ROE Continue To Surpass The Industry Average?

Feb 08

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: SUVENPHAR 'nin kısa vadeli varlıkları ( ₹11.7B ) kısa vadeli yükümlülüklerini ( ₹2.4B ) aşıyor.

Uzun Vadeli Yükümlülükler: SUVENPHAR şirketinin kısa vadeli varlıkları ( ₹11.7B ) uzun vadeli yükümlülüklerini ( ₹2.4B ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: SUVENPHAR şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: SUVENPHAR 'nin borç/öz sermaye oranı son 5 yılda 18.7% seviyesinden 0.4% seviyesine düştü.

Borç Kapsamı: SUVENPHAR 'nin borcu işletme nakit akışı ( 3129.5% ) tarafından iyi bir şekilde karşılanmaktadır.

Faiz Kapsamı: SUVENPHAR 'in borcuna ilişkin faiz ödemeleri EBIT ( 46.6 x kapsam) tarafından iyi bir şekilde karşılanmaktadır.

Bilanço

Sağlıklı şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/01/03 18:14
Gün Sonu Hisse Fiyatı	2025/01/03 00:00
Kazançlar	2024/09/30
Yıllık Kazançlar	2024/03/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

Suven Pharmaceuticals Limited 4 Bu analistlerden 0, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Rohit Bhat	Batlivala & Karani Securities India Pvt. Ltd.
Nikhil Shetty	BP Wealth Management Private Limited
Vinod T.P.	Geojit Financial Services Ltd.

Suven Pharmaceuticals Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

These 4 Measures Indicate That Suven Pharmaceuticals (NSE:SUVENPHAR) Is Using Debt Safely

Does Suven Pharmaceuticals (NSE:SUVENPHAR) Have A Healthy Balance Sheet?

These 4 Measures Indicate That Suven Pharmaceuticals (NSE:SUVENPHAR) Is Using Debt Safely

Here's Why Suven Pharmaceuticals (NSE:SUVENPHAR) Can Manage Its Debt Responsibly

Does Suven Pharmaceuticals (NSE:SUVENPHAR) Have A Healthy Balance Sheet?

Recent updates

Suven Pharmaceuticals Limited to Report Q3, 2025 Results on Feb 12, 2025

Price target increased by 51% to ₹1,435

Suven Pharmaceuticals Limited (NSEI:SUVENPHAR) agreed to acquire an unknown minority stake in NJ BIO, Inc. for $49.4 million.

New major risk - Revenue and earnings growth

Second quarter 2025 earnings released: EPS: ₹3.23 (vs ₹3.13 in 2Q 2024)

Suven Pharmaceuticals Limited to Report Q2, 2025 Results on Nov 12, 2024

Suven Pharmaceuticals Limited Announces the Resignation of Brian Shaughnessy as Chief Commercial Officer and Senior Management Personnel

Suven Pharmaceuticals Limited Announces Board Changes

Suven Pharmaceuticals Limited Announces Company Secretary and Compliance Officer Changes

Suven Pharmaceuticals Limited to Report Q1, 2025 Results on Aug 09, 2024

Full year 2024 earnings: EPS and revenues miss analyst expectations

Suven Pharmaceuticals Limited, Annual General Meeting, Aug 09, 2024

Suven Pharmaceuticals Limited, Annual General Meeting, Aug 09, 2024

Investor sentiment improves as stock rises 18%

Suven Pharmaceuticals Limited (NSEI:SUVENPHAR) agreed to acquire 67.50% stake in Sapala Organics Private Limited for INR 2.3 billion.

Full year 2024 earnings released: EPS: ₹11.80 (vs ₹16.16 in FY 2023)

Suven Pharmaceuticals Limited (NSEI:SUVENPHAR) agreed to acquire Cohance Lifesciences Limited.

Consensus revenue estimates fall by 14%

Price target increased by 17% to ₹710

Third quarter 2024 earnings released: EPS: ₹1.84 (vs ₹4.23 in 3Q 2023)

Suven Pharmaceuticals Limited to Report Q3, 2024 Results on Feb 05, 2024

Suven Pharmaceuticals Limited Announces CFO Changes

Suven Pharmaceuticals Limited Announces CFO Changes

Suven Pharmaceuticals Limited Appoints Dr. Vetukuri Venkata Naga Kali Vara Prasada Raju as Managing Director

Suven Pharmaceuticals Limited Approves Interim Dividend for the Financial Year 2023-24

Suven Pharmaceuticals Limited Proposes Interim Dividend for the Financial Year 2022-23

Second quarter 2024 earnings released: EPS: ₹3.13 (vs ₹2.83 in 2Q 2023)

Suven Pharmaceuticals Limited, Annual General Meeting, Dec 15, 2023

Suven Pharmaceuticals Limited to Report Q2, 2024 Results on Nov 09, 2023

First quarter 2024 earnings released: EPS: ₹4.74 (vs ₹4.22 in 1Q 2023)

Suven Pharmaceuticals Limited to Report Q1, 2024 Results on Aug 08, 2023

Full year 2023 earnings: EPS exceeds analyst expectations

Insider recently sold ₹3.4m worth of stock

Third quarter 2023 earnings released: EPS: ₹4.23 (vs ₹6.29 in 3Q 2022)

Advent International Corporation agreed to acquire 50.1% stake in Suven Pharmaceuticals Limited (NSEI:SUVENPHAR) from Jasti Family for INR63 billion.

These 4 Measures Indicate That Suven Pharmaceuticals (NSE:SUVENPHAR) Is Using Debt Safely

High number of new directors

Second quarter 2023 earnings released: EPS: ₹2.83 (vs ₹3.81 in 2Q 2022)

Blackstone, Advent Reportedly to Buy Stake in Suven Pharma

Robust Earnings May Not Tell The Whole Story For Suven Pharmaceuticals (NSE:SUVENPHAR)

Full year 2022 earnings: EPS exceeds analyst expectations

Suven Pharmaceuticals Limited to Report Q4, 2023 Results on May 15, 2023

Does Suven Pharmaceuticals (NSE:SUVENPHAR) Have A Healthy Balance Sheet?

Full year 2022 earnings: EPS exceeds analyst expectations

Suven Pharmaceuticals Limited, Annual General Meeting, Aug 18, 2022

Suven Pharmaceuticals Limited to Report Q4, 2022 Results on May 09, 2022

High number of new and inexperienced directors

Suven Pharmaceuticals Limited (BSE:543064) agreed to acquire Casper Pharma Private Limited for approximately $20 million.

Suven Pharmaceuticals Limited (NSE:SUVENPHAR) Investors Are Less Pessimistic Than Expected

Investor sentiment improved over the past week

Here's Why We Think Suven Pharmaceuticals (NSE:SUVENPHAR) Is Well Worth Watching

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Suven Pharmaceuticals to Evaluate the Acquisition Opportunity of Casper Pharma

Suven Pharmaceuticals Limited to Report Q3, 2022 Results on Feb 08, 2022

These 4 Measures Indicate That Suven Pharmaceuticals (NSE:SUVENPHAR) Is Using Debt Safely

Second quarter 2022 earnings released: EPS ₹3.81 (vs ₹2.91 in 2Q 2021)

Do Suven Pharmaceuticals's (NSE:SUVENPHAR) Earnings Warrant Your Attention?

Full year 2021 earnings released: EPS ₹14.23 (vs ₹12.45 in FY 2020)

Upcoming dividend of ₹1.00 per share

Here's Why Suven Pharmaceuticals (NSE:SUVENPHAR) Can Manage Its Debt Responsibly

Price target increased to ₹572

Analysts Have Made A Financial Statement On Suven Pharmaceuticals Limited's (NSE:SUVENPHAR) Full-Year Report

Full year 2021 earnings released: EPS ₹14.23 (vs ₹12.45 in FY 2020)

With EPS Growth And More, Suven Pharmaceuticals (NSE:SUVENPHAR) Is Interesting

Does Suven Pharmaceuticals (NSE:SUVENPHAR) Have A Healthy Balance Sheet?

New 90-day high: ₹507

Can Suven Pharmaceuticals Limited's (NSE:SUVENPHAR) ROE Continue To Surpass The Industry Average?

Suven Pharmaceuticals Limited to Report Q3, 2021 Results on Feb 10, 2021

Blackstone, CVC & Warburg Reportedly in Race to Buy Suven Pharma

New 90-day high: ₹503